Jeffrey M. Ostrove, Ph.D. named chief executive officer Proprietary technology based on pioneering work from the lab of Eugene (Gene) Yeo, Ph.D. of UC San Diego SAN DIEGO, May 22, 2019-- Locana, Inc., a leading RNA-targeting gene therapy company, announced today the close of a $55 million Series A financing led by ARCH Venture Partners with participation from Temasek and Lightstone Ventures, all existing investors. New investors include UCB Ventures and GV (formerly Google Ventures).